

FACULTY DISCLOSURE STATEMENTS

The symposium faculty and contributing authors reported the following:

Nicholas J. Coupland, M.B., Ch.B., M.R.C.Psych.

Grant/research support: Parke-Davis.

Jonathan R. T. Davidson, M.D. *Grant/research support:*

Lilly, Organon, Pfizer, SmithKline Beecham, Solvay. *Consultant:* Bristol-Myers Squibb, DuPont, Forest, Janssen, Lilly, Parke-Davis, Pfizer, SmithKline Beecham, Wyeth-Ayerst. *Honoraria:* Bristol-Myers Squibb, Lilly, Parke-Davis, Pfizer, SmithKline Beecham, Wyeth-Ayerst.

John H. Greist, M.D. *Grant/research support:* Lilly,

Novartis, Organon, Parke-Davis, Pfizer, SmithKline Beecham, Solvay. *Consultant:* Lilly, Novartis, Organon, Parke-Davis, Pfizer, SmithKline Beecham, Solvay. *Honoraria:* Lilly, Novartis, Organon, Parke-Davis, Pfizer, SmithKline Beecham, Solvay. *Speakers or advisory boards:* Lilly, Novartis, Organon, Parke-Davis, Pfizer, SmithKline Beecham, Solvay. *Major stock shareholder:* Healthcare Technology Systems, LLC.

Richard G. Heimberg, Ph.D. None reported.

James W. Jefferson, M.D. *Grant/research support:*

Abbott Laboratories, Bristol-Myers Squibb, Forest, Glaxo Wellcome, Janssen, Lilly, Organon, Parke-Davis, Pfizer, SmithKline Beecham, Solvay, Warner-Lambert. *Consultant:* Glaxo Wellcome, Novartis, Parke-Davis, Scios, Tap Pharmaceuticals. *Honoraria:* Bristol-Myers Squibb, Forest, Glaxo Wellcome, Janssen, Lilly, Parke-Davis, Pfizer, Pharmacia & Upjohn, G.D. Searle, SmithKline Beecham, Solvay, Wyeth-Ayerst. *Minor stockholder:* Glaxo Wellcome, Scios. *Major stockholder:* Healthcare Technology Systems, LLC. *Other financial or material support:* Various, from time to time, from the pharmaceutical companies listed above.

David J. Katzelnick, M.D. *Grant/research support:* Abbott Laboratories, AstraZeneca, Glaxo Wellcome, Novartis, Pfizer, Solvay. *Consultant:* Abbott Laboratories, Pfizer. *Speakers or advisory boards:* Abbott Laboratories, CoCensys, Forest, Lilly, Novartis, Parke-Davis, Pfizer, Pharmacia & Upjohn, SmithKline Beecham. *Minor stockholder:* Johnson & Johnson. *Major stockholder:* Healthcare Technology Systems, LLC. *Other financial or material support:* Various, from time to time, from the pharmaceutical companies listed above.

Ariel J. Lang, Ph.D. None reported.

R. Bruce Lydiard, M.D., Ph.D. *Grant/research support:* Bristol-Myers Squibb, Glaxo Wellcome, Lilly, Parke-Davis, Pfizer, SmithKline Beecham. *Consultant:* AstraZeneca, Bristol-Myers Squibb, Forest, Glaxo Wellcome, Hoffmann-La Roche, Lilly, Parke-Davis, Pfizer, SmithKline Beecham. *Speakers or advisory boards:* Bristol-Myers Squibb, Forest, Glaxo Wellcome, Lilly, Parke-Davis, Pharmacia & Upjohn, SmithKline Beecham.

Franklin R. Schneier, M.D. *Grant/research support:* Solvay, Somerset. *Speakers or advisory boards:* SmithKline Beecham.

Murray B. Stein, M.D. *Grant/research support:* Bristol-Myers Squibb, Forest, Hoffmann-La Roche, Lilly, Novartis, Parke-Davis, Pfizer, SmithKline Beecham, Solvay. *Consultant:* Forest, Hoffmann-La Roche, Janssen Research Foundation, SmithKline Beecham, Solvay. *Honoraria:* Bristol-Myers Squibb, Hoffmann-La Roche, Lilly, Pfizer, Pharmacia & Upjohn, SmithKline Beecham, Solvay.

DISCLOSURE OF DRUG USE

The articles in this supplement discuss off-label, experimental, or investigational uses of the following anticonvulsants and psychotropic medications for the treatment of social phobia:

Nicholas J. Coupland, M.B., Ch.B., M.R.C.Psych.

Selective serotonin reuptake inhibitors (e.g., fluoxetine, fluvoxamine), monoamine oxidase inhibitors (phenelzine), β -blockers (atenolol, propranolol), benzodiazepines (clonazepam), anticonvulsants (gabapentin), pregabalin (investigational compound)

Richard G. Heimberg, Ph.D.

Selective serotonin reuptake inhibitors (fluoxetine), monoamine oxidase inhibitors (phenelzine), benzodiazepines (alprazolam, clonazepam)

James W. Jefferson, M.D.

β -Blockers (nadolol), benzodiazepines (alprazolam, bromazepam,^a clonazepam, diazepam), anticonvulsants (gabapentin, valproate), pregabalin (investigational compound)

David J. Katzelnick, M.D., and John H. Greist, M.D.

None discussed

Ariel J. Lang, Ph.D., and Murray B. Stein, M.D.

None discussed

R. Bruce Lydiard, M.D., Ph.D.

Selective serotonin reuptake inhibitors, monoamine oxidase inhibitors (phenelzine), anticonvulsants (gabapentin)

Franklin R. Schneier, M.D.

Selective serotonin reuptake inhibitors (citalopram, fluoxetine, fluvoxamine, sertraline), monoamine oxidase inhibitors (phenelzine, selegiline, tranylcypromine), reversible inhibitors of monoamine oxidase (brofaromine,^a moclobemide^a), β -blockers (atenolol), benzodiazepines (alprazolam, clonazepam), other antidepressants or anxiolytics (bupropion, buspirone, nefazodone, venlafaxine), anticonvulsants (gabapentin)

^aNot marketed in the United States.